Clinical trials: Hematological Malignancies
Polycythemia Vera
A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera
Jakavi® therapy for polycythemia vera (PV) has so far been studied exclusively in clinical trials and at selected clinical trial centres.
- Trial name
- PAVE (NCT05853445)
- Testing
- Jakavi
- Where
- 99 sites in Germany
- Volunteers
- 467 people
- Sponsor
- Novartis Pharmaceuticals
Cancer
Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies
This is a two-part study in subjects with hematologic malignancies designed to find the maximum tolerated dose (MTD) of GSK690693 (Part 1).
- Trial name
- NCT00666081
- Testing
- GSK690693
- Sponsor
- GlaxoSmithKline
Chronic Lymphocytic Leukemia (CLL)
Clinico-hematological and Molecular Characteristics of Chronic Lymphocytic Leukemia Patients
the goal of this study is To describe the clinical, hematologic, and cytogenetic characteristics of CLL cases. The main questions it aims to answer are: 1.
- Trial name
- NCT07162532
- Testing
- 1 Complete blood picture (CBC) with blood film, lymphocytic count 2 and viral hepatitis 3 Immunophenotyping 4 LDH 5 Coomb's tests ,deletion 17p,IGVH mutation,ESR
- Volunteers
- 45 people
- Sponsor
- Assiut University
Acute Myeloid Leukemia, Myelodysplasia
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia
The primary objective of this study is to examine transplant related mortality (TRM) at 100 days <30%. A TRM of >50% is considered unacceptable.
- Conditions
- Acute Myeloid Leukemia, Myelodysplasia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT00513175
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of California, San Francisco
Acute Myelogenous Leukemia, B-cell Lymphoma
FT516 in Subjects With Advanced Hematologic Malignancies
This is a Phase 1/1b dose-finding study of FT516 as monotherapy in acute myeloid leukemia (AML) and in combination with CD20 directed monoclonal antibodies in B-cell lymphoma.
- Trial name
- NCT04023071
- Testing
- FT516, Rituximab, Obinutuzumab
- Where
- 7 sites in United States
- Volunteers
- 72 people
- Sponsor
- Fate Therapeutics
Herpes Zoster
Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers
The purpose of this study is to evaluate the safety and immunogenicity of GSK Biologicals' vaccine GSK1437173A in subjects aged 18 years and older with blood cancers.
- Trial name
- NCT01767467
- Testing
- Herpes zoster vaccine (GSK 1437173A)
- Where
- 86 sites in United States, Australia and 19 more
- Volunteers
- 568 people
- Sponsor
- GlaxoSmithKline
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment
This phase III trial compares BBT-CI to HEAL for the reduction of insomnia in patients with stage I-IV cancer who are receiving cancer treatment. Cancer treatment can cause side effects such as sleep problems.
- Trial name
- BBT-II (NCT04829539)
- Testing
- Behavioral Intervention, Electronic Health Record Review, Quality-of-Life Assessment
- Where
- 153 sites in United States
- Volunteers
- 400 people
- Sponsor
- University of Rochester NCORP Research Base
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy
This is an open-label, single arm phase 1 study to evaluate the dose-limiting toxicity, maximum tolerated dose, and recommended phase II dose of Clioquinol in patients with relapsed or refractory hematologic malignancies.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Myelodysplasia
- Trial name
- NCT00963495
- Testing
- Clioquinol
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- University Health Network, Toronto
Anemia, Graft Versus Host Disease
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Bone marrow that has been treated to remove certain white blood cells may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy, and may reduce the chance of developing…
- Conditions
- Anemia, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00003398
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Maryland, Baltimore
Hematologic Malignancy
A Prospective Study of Conventional Bone Marrow Biopsy Versus Portomar(TM) Biopsy
This is a self-controlled, prospective trial. The objective of this trial is to evaluate the efficacy and safety of the Portomar(TM) device for bone marrow biopsy.
- Trial name
- NCT05583734
- Testing
- Portomar(TM) Device
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Aperture Medical Technology, LLC
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies
This study collects information about complications and clinical response in cancer patients treated with anti-VEGF-related therapies.
- Trial name
- NCT05108519
- Testing
- Electronic Health Record Review
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Myeloma
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
The goal of this clinical research study is to learn if giving genetically changed immune cells, called T-cells, after chemotherapy will improve the response to a stem cell transplant.
- Conditions
- Leukemia, Myeloma, Myeloproliferative Diseases
- Trial name
- NCT01875237
- Testing
- Fludarabine, Melphalan, Alemtuzumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Lymphoma
Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00004145
- Testing
- anti-thymocyte globulin, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Chicago
Hematological Malignancy, Bone Marrow Failure Syndrome
Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation
The purpose of this study is to determine whether Eltrombopag may shorten time to platelet engraftment after allogeneic cord blood transplantation.
- Trial name
- NCT01757145
- Testing
- Eltrombopag
- Where
- 2 sites in Israel
- Volunteers
- 20 people
- Sponsor
- Rabin Medical Center
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies
This clinical pilot trial is intended to evaluate the feasibility, efficacy and safety of hematopoietic stem cell transplantation (HSCT) from Human Leukocyte Antigen (HLA)-mismatched related donors for children and young adults…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia
- Trial name
- NCT02566395
- Testing
- Radiation, Cyclophosphamide, Donor Lymphocyte Infusion (DLI)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwell Health
Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
This phase II trial studies the side effects and best dose of radiation therapy and to see how well it works in treating patients with cancer that has spread to other places in the body (metastatic) or has increased in size after…
- Trial name
- NCT02710253
- Testing
- External Beam Radiation Therapy, Laboratory Biomarker Analysis, Stereotactic Body Radiation Therapy
- Where
- 5 sites in United States
- Volunteers
- 214 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatic Impairment
Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment
The main purpose of this study is to evaluate the effect of varying degrees of impaired hepatic function (by Child Pugh classification) on the plasma PK of siremadlin after a single oral dose.
- Trial name
- NCT05599932
- Testing
- Siremadlin
- Where
- 3 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Lymphoma, Multiple Myeloma
A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies
The purpose of this clinical trial is to learn about how safe and tolerable is the study medicine (called maplirpacept (PF-07901801)) when taken for the treatment of lymphoma or multiple myeloma (a type of cancer that affects…
- Trial name
- NCT05567887
- Testing
- maplirpacept (PF-07901801)
- Where
- 4 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Pfizer
Leukemia, Acute Myeloid, Myelodysplastic Syndromes
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to treatment with standard therapies or who have relapsed after treatment.
- Conditions
- Leukemia, Acute Myeloid, Myelodysplastic Syndromes, Classical Hodgkin Lymphoma, Leukemia, B-cell
- Trial name
- NCT05362773
- Testing
- MGD024
- Where
- 7 sites in United States
- Volunteers
- 130 people
- Sponsor
- MacroGenics
Sepsis, Septic Shock
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
Sepsis remains the leading cause of ICU admission in neutropenic patients. This condition remains associated with a high morbidity and mortality, with hospital mortality of 60% when vasopressors are required.
- Conditions
- Sepsis, Septic Shock, Hematologic Malignancy, Tumor
- Trial name
- NCT05443854
- Testing
- Aminoglycosides intervention, Lack of protective isolation intervention, No systematic aminoglycosides intervention - standard arm
- Volunteers
- 340 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.